Evidence map›Paper›PMID 41280907›Full record

ArticleFrontiers in immunology2025

Correction: Unveiling the NEFH+ malignant cell subtype: insights from single-cell RNA sequencing in prostate cancer progression and tumor microenvironment interactions.

Jie Wang, Fu Zhao, Qiang Zhang, Zhou Sun, Zhikai Xiahou, Changzhong Wang, Yan Liu, Zongze Yu

Abstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors.

Jie Wang *Department of Urology, The Second People's Hospital of Meishan City, Meishan, Sichuan, China.
Fu Zhao *The First Clinical Medical College of Shandong University of Traditional Chinese Medicine, Jinan, China.
Qiang Zhang *Department of Urology, The Second People's Hospital of Meishan City, Meishan, Sichuan, China.
Zhou Sun *Department of Urology, China-Japan Union Hospital of Jilin University, Changchun, Jilin, China.
Zhikai XiahouChina Institute of Sport and Health Science, Beijing Sport University, Beijing, China.
Changzhong WangDepartment of Urology, The First People's Hospital of Jiangxia District, Wuhan, Hubei, China.
Yan LiuDepartment of Urology, Xiangyang Central Hospital, Affiliated Hospital of Hubei University of Arts and Science, Xiangyang, Hubei, China.
Zongze YuDepartment of Urology, The Second People's Hospital of Meishan City, Meishan, Sichuan, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

[This corrects the article DOI: 10.3389/fimmu.2024.1517679.].

Indexed as

drug discoverymulti-omicsprecision medicineprostate cancersingle-cell RNA sequencingtumor heterogeneity

Identifiers

PMID41280907
PMCPMC12637059

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.